Biogen (NASDAQ:BIIB) is scheduled to announce Q3 earnings results on Wednesday, October 21st, before market open.The consensus EPS Estimate is $8.07 (-12.0% Y/Y) and the consensus Revenue Estimate is $3.34B (-7.2% Y/Y).Analyst expects R&D expense of $582.1M.Over the last 2 years, BIIB has beaten EPS estimates 100% of the time and has beaten revenue estimates 100% of the time.Over the last 3 months, EPS estimates have seen 10 upward revisions and 16 downward.
Biogen Inc (BIIB) - Biogen Inc - Company Announces New $5.0 Billion Share Repurchase Authorization. Revenue is expected to be $3.38 Billion Adjusted EPS is expected to be $8.20 Next Quarter Revenue Guidance is expected to be $3.25 Billion Next Quarter EPS Guidance is expected to be $6.96 More details on our Analysts Page.
Biogen Inc. (NASDAQ:BIIB) went down by -0.61% from its latest closing price compared to the recent 1-year high of $374.99. The company's stock price has collected -8.35% of loss in the last five trading sessions. Barron's reported 11 hours ago that A Crucial FDA Hearing Looms for Biogen Alzheimer's Drug Biogen Inc.
Cambridge, Massachusetts-based Biogen reported biosimilar revenues up 13% for the third quarter of 2020, to $208 million. Biogen markets etanercept (Benepali), adalimumab (Imraldi), and infliximab (Flixabi) biosimilars. Benepali revenues were up 7%, or $124 million vs 116 million in the year-ago third quarter; Imraldi, up 14%, or $56 million vs $49 million; and Flixabi, up 49%, or $27 million vs $18 million.
Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the 'substantial evidence' standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (), Adocia () and Biogen () with bullish sentiments. Ligand Pharma (LGND) In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma, with a price target of $229.00.
Summary of the Multiple Sclerosis Therapies Market Report Several factors are related to Multiple Sclerosis Therapies Market growth, such as growing demand across different application areas, development in the research sector and increasing product applications across different geographies.
(RTTNews) - While reporting financial results for the third quarter on Wednesday, Biogen Inc. (BIIB) trimmed its earnings, adjusted earnings and revenue guidance for the full-year 2020, due to the impact of multiple generic entrants for its multiple sclerosis drug Tecfidera in th
Drugmaker Biogen Inc reported a 54.6% fall in third-quarter profit on Wednesday, hurt by costs related to its collaboration with Denali Therapeutics Inc . Net income attributable to Biogen fell to $701.5 million, or $4.46 per share, in the quarter ended Sept. from $1.55 billion, or $8.39 per share, a year earlier.
Yahoo Finance's Emily McCormick joins The First Trade with Alexis Christoforous and Brian Sozzi to discuss recent earnings reports from Verizon, Abbott and Biogen.
Here's a roundup of top developments in the biotech space over the last 24 hours. (Biotech Stocks Hitting 52-week Highs Oct. 20) Aileron Therapeutics Inc (NASDAQ: ALRN) Anchiano Therapeutics Ltd - ADR (NASDAQ: ANCN) Athira Pharma Inc (NASDAQ: ATHA) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) BioSpecifics Technologies Corp.
AutoNation Reports Record Profit on Higher-Than-Expected Sales By Investing.com By Christiana Sciaudone Investing.com -- The car market is back with a vengeance, and so is AutoNation (NYSE:AN). The country's largest auto dealer chain posted record profit in...
Biogen Inc. (NASDAQ:BIIB) - Investment analysts at Oppenheimer dropped their Q3 2020 earnings per share estimates for shares of Biogen in a research report issued to clients and investors on Sunday, October 18th. Oppenheimer analyst J. Olson now anticipates that the biotechnology company will pos
Ionis ( IONS) recently completed the acquisition of its mostly owned spin-off, Akcea Therapeutics. The spin-off of Akcea began back in 2015, when Ionis was still called Isis Pharmaceuticals. I questioned the point of it when the company had its IPO in 2017.
Finviz Chart w/author annotations The name says it all. Almost a decade after dipping their toe in gene therapy, Biogen (NASDAQ: BIIB) created a focused internal team called the Gene Therapy Accelerated Unit or GTxAU.
A U.S. Food and Drug Administration committee is likely to give an unfavorable review next month for a key Biogen ( BIIB) Alzheimer's treatment, an analyst said in a research report to clients on Monday, an action that could weigh on BIIB stock. It comes as BIIB earnings are due this week.
Abarca, a pharmacy benefit manager (PBM) that is disrupting the industry with a new approach to technology and business practices released a new case study detailing a value-based agreement with Biogen Inc. (NASDAQ: BIIB) for Avonex® (interferon beta-1a) and Tecfidera® (dimethyl fumarate), select products in the drug maker's leading multiple sclerosis (MS) portfolio.
Acorda Therapeutic (NASDAQ: ACOR) jumps 69% in pre-market trading, as it announces receiving a $15M milestone payment from Biogen International GmbH. The payment is with respect to Acorda's license agreement with Biogen, based on Biogen's ex-U.S. net sales of Fampyra exceeding $100M over the four consecutive quarters ending with 3Q20.
Recent changes on the market indicate that the prices of the shares of a leading Biotechnology company based in the USA, Biogen, are down 4%. The movements follow the news of some experts claiming that the US Food and Drug Administration committee is more likely to not give Biogen's Alzheimer's treatment favorable review next month.
Equities analysts expect Biogen Inc. (NASDAQ:BIIB) to post $3.35 billion in sales for the current quarter, Zacks reports. Twenty Eight analysts have provided estimates for Biogen's earnings, with the lowest sales estimate coming in at $3.08 billion and the highest estimate coming in at $3.55 billion